Print

Arno Therapeutics to Collaborate With Clarient, Inc. for Development of Diagnostic Test  
5/10/2013 9:33:45 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., May 10, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Clarient Diagnostic Services, Inc., a GE Healthcare company, and leading provider of cancer diagnostic testing, to develop a diagnostic test to identify activated progesterone receptors in endometrial cancer. The diagnostic test is intended to be used in the development of Arno's investigational progestin receptor antagonist, onapristone. In pre-clinical studies, the presence of activated progesterone receptors (APR) has shown to be predictive of onapristone activity.

Help employers find you! Check out all the jobs and post your resume.

//-->